[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibiotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibiotic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,84,112,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879",false,"NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.",true,"ALL","1 Day","35 Days",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[28,29,30,31],"Antibiotic","Allergic Diseases","Infants","Probiotic",[33,34,35,36],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases","NOT_YET_RECRUITING","2026-05-06",{"date":40,"type":41},"2026-05-11","ACTUAL",{"date":43,"type":22},"2026-04-17",{"date":45,"type":22},"2027-10-31",{"name":47,"class":48},"Peking University Third Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100613517","early-antibiotics-adaptation-in-severe-pneumoniathe-early-adapt-study-100613517","NCT07267624","EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study)","EARLY Antibiotics aDaptation in Ventilator-Acquired-Pneumonia Treatment After Implementation of a Broad-Panel Respiratory Multiplex PCR Test: A Multicenter Randomized Control Trial Conducted In Swiss Intensive Care Units. The EARLY ADAPT Study.","EARLY ADAPT","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old)\n* Hospitalized in intensive care with invasive mechanical ventilation ≥ 48 hours\n* Administration of antimicrobial therapy for suspected VAP at the time of inclusion.\n* Expected survival \\> 96 hours.\n\nExclusion Criteria:\n\n* Enrollment prior to the current trial\n* Participation in an interventional study on the management of AMR that has a direct impact on antibiotic therapy practices.","18 Years",{"count":60,"type":22},170,[25],"The objective of the study is to determine whether rapid multiplex PCR testing of respiratory samples can reduce exposure to broad-spectrum antibiotics in intensive care unit patients with suspected or confirmed ventilator-associated pneumonia, compared to standard diagnostic methods.\n\nAs secondary objectives, the investigators will study antibiotic management and overall antibiotic consumption, as well as escalation or de-escalation events. The investigators will study the potential clinical impact of using multiplex PCR to see if the length of stay in the intensive care unit is reduced, as well as the duration of mechanical ventilation.",[64,28,65,66,67],"VAP - Ventilator Associated Pneumonia","Antibiotic Stewardship","Antibiotic Prescribing for Acute Respiratory-tract Infections","Intensive Care (ICU)",[69,70,71,72,73,74],"ventilator Associated Pneumonia (VAP)","antibiotic","PCR multiplex","intensive care","broad spectrum antibiotic","stewardship","2026-04-28",{"date":77,"type":41},"2026-04-29",{"date":79,"type":22},"2026-06-05",{"date":81,"type":22},"2028-06-30",{"name":83,"class":48},"University Hospital, Geneva",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":49},"100611643","study-evaluating-the-impact-of-using-triplex-rapid-diagnostic-tests-sars-cov-2influenzarsv-on-antibiotic-prescribing-100611643","NCT07243249","Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2\u002FInfluenza\u002FRSV) on Antibiotic Prescribing","Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2\u002FInfluenza\u002FRSV) on Antibiotic Prescribing in the General Population in Community Settings","TROD-VILLE","Inclusion Criteria:\n\n1. Age ≥ 1 year\n2. Presenting with:\n\n   * Either fever (temperature \\> 38°C measured by patient or physician) within the past 72 hours, and one of the following symptom combinations:\n\n     1. Rhinorrhea (white, yellow, or green discharge) and\u002For nasal obstruction, and cough\n     2. Body aches, cough, and fatigue\n     3. Odynophagia and negative strepto-test\n     4. Cough\n     5. Otalgia\n   * Or suspicion of lower respiratory tract infection: signs of infection (respiratory rate \\> 20\u002Fmin, heart rate \\> 100\u002Fmin, fatigue, Body aches, chills, or fever), associated with pulmonary localization signs \\[cough, sputum, chest pain, auscultatory abnormality (rhonchi, crackles, or wheezing)\\]\n3. Affiliation with the national health insurance system\n4. Informed consent obtained from the adult participant, or from the person(s) with parental authority for a minor participant\n\nExclusion Criteria:\n\n1. Requirement for hospitalization\n2. Presence of a non-respiratory infection requiring concomitant antibiotic treatment.\n3. Patients covered by State Medical Aid (AME)","1 Year",{"count":94,"type":22},2000,[25],"Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).\n\nThese illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases.\n\nHowever, the excessive use of antibiotics contributes to the development of bacterial resistance, which is a major public health issue.\n\nThe aim of this study is to better understand whether the use of a rapid test (called TROD), which can quickly identify certain respiratory viruses, can help doctors reduce unnecessary antibiotic prescriptions for these infections. The test will be performed using a swab gently inserted into the nose.",[98,28],"Respiratory Infections",[100,28,101],"Respiratory infections","Rapid diagnostic tests","RECRUITING","2026-01-13",{"date":105,"type":41},"2026-01-14",{"date":107,"type":41},"2026-01-07",{"date":109,"type":22},"2026-04",{"name":111,"class":48},"Assistance Publique - Hôpitaux de Paris",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100611333","the-impact-of-irrisept-in-reducing-urinary-tract-infection-during-urethral-catheter-removal-100611333","NCT07239219","The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","To Determine the Efficacy of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","Inclusion Criteria:\n\n1. Presenting to the urology clinic for catheter removal\n2. Must be 18 years or older.\n3. The patient must be able to understand and willing to provide informed consent as described in this study protocol.\n4. Must be willing to complete a post-catheter removal survey\n\nExclusion Criteria:\n\n1. Allergy or adverse reaction to chlorohexidine gluconate\n2. Under the age of 18\n3. Refuse to provide informed consent\n4. On antibiotic therapy for any indication.\n5. Women who are pregnant or breastfeeding\n6. Signs of skin or systemic infection\n7. Patients undergoing catheter exchange",{"count":120,"type":22},300,[25],"Given the high burden of post-catheter removal UTIs, this study aims to evaluate Irrisept instillation as a non-antibiotic intervention to reduce infection rates. By comparing Irrisept to saline irrigation, the study will provide critical insights into the efficacy of antiseptic bladder irrigation in preventing UTIs while minimizing antibiotic use. If successful, this approach could lead to new clinical guidelines for catheter removal protocols, improving patient outcomes and reducing healthcare costs.",[124,28,125],"Urinary Tract Infection","Catheter Infection",[127,70,128,129],"UTI","Catheter infection","CAUTI","2025-11-16",{"date":132,"type":41},"2025-11-20",{"date":134,"type":22},"2025-12-31",{"date":136,"type":22},"2028-01-01",{"name":138,"class":48},"Ohio State University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":16,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100545177","phase-4-the-effect-of-different-antibiotic-protocols-on-peri-implant-tissue-health-100545177","NCT06378502","The Effect of Different Antibiotic Protocols on Peri-implant Tissue Health","The Effect of Different Antibiotic Protocols for Dental Implant Surgery on Peri-implant Tissue Health and on Oral Microbiome and Resistome","Inclusion Criteria:\n\nHealthy volunteers requiring one single implant or partial implant-supported rehabilitation in an edentulous area of the posterior mandible or maxilla\n\nExclusion Criteria:\n\n* Patients unable to commit to follow-up\n* General contraindications to implant surgery\n* Immuno-suppressed\u002Fimmune-compromised patients\n* Patients irradiated in the head and\u002For neck\n* Uncontrolled diabetes\n* Pregnancy, childbearing potential, breastfeeding\n* Smoking habit\n* Untreated periodontal disease (Caton et al, J Clin Periodontol 2018)\n* Poor oral hygiene and motivation (plaque index \\> 20%)\n* Addiction to alcohol or drugs\n* Psychiatric problems and\u002For unrealistic expectations\n* Patients with an acute infection (abscess) or suppuration in the site intended for implant placement\n* Patients treated or under treatment with intravenous amino-bisphosphonates\n* Patients referred only for implant placement if the follow-up cannot be done at the treatment center\n* Patients participating in other studies, if the present protocol could not be fully adhered to\n* Patients with allergy\u002Fhypersensitivity to penicillin or drug excipients\n* Patients recently treated with antibiotics for other indications","35 Years","65 Years",{"count":149,"type":22},80,[151],"PHASE4","The aim of the present project (non-inferiority trial) is to evaluate the effect of different antibiotic strategies (long-span vs. short-span) for implant surgery on peri-implant tissue health, oral microbiome (included resistome) and salivary MiRNomics in healthy patients.",[28],"2024-04-17",{"date":156,"type":41},"2024-04-22",{"date":158,"type":22},"2024-05-03",{"date":160,"type":22},"2026-06-30",{"name":162,"class":48},"Universita degli Studi di Genova"]